Suppression of local and systemic responses in streptococcal cell wall-induced acute inflammation of the air pouch by cyclosporine A. Comparison with the effects of two anti-inflammatory bis-benzimidazoles. by Geratz, J. Dieter et al.
American Journal of Pathology, Vol. 142, No. 4, April 1993
Copyright American Societyfor Investigative Pathology
Suppression of Local and Systemic Responses
in Streptococcal Cell Wall-Induced Acute
Inflammation of the Air Pouch by Cyclosporine A
Comparison with the Effects of Two Anti-Inflammatory
Bis-Benzimidazoles
J. Dieter Geratz,* Katherine B. Pryzwansky,*
John H. Schwab,t Sonia K. Anderle,t and
Richard R. Tidwell*t
From the School ofMedicine, Departments ofPathology
and Microbiology and Immunology,t and the School of
Pharmacy, Department ofMedicinal Chemistry,* University
ofNorth Carolina at Chapel Hill, Chapel Hill, North
Carolina
Injection of streptococcus group A ceU waU-
derivedpeptidoglycanpolysaccharide into a sub-
cutaneous airpouch causes local outpouring of
neutrophils and macrophages and distant he-
mopoietic proliferation in spleen and bone mar-
row. CyclosporineA (CyA) suppressed neutrophil
accumulation and aU ceU lines of hemopoiesis.
trans-1,2-Bis(5-amidino-2-benzimidazolyl)ethene
(BBE) also interfered with neutrophil exudation,
yet reduced only the erythroid component ofthe
hemopoietic process. The ethane analogue of
BBE, on the otherhand, didnotprevent neutrophil
emigration, but held down splenic erythropoiesis
and myelopoiesis. AU three compounds stimu-
lated streptococcusgroupA ceUwaU-derivedpep-
tidoglycanpolysaccharide uptake bypouch mac-
rophages, CyA being the least active. BBE and its
ethane analogue also produced a shift of wear-
and-tear pigment from large numbers of smaU
splenic macro-phages into smaUnumbers oflarge
macrophages. Thepouch model is very useful in
the study of anti-inflammatory compounds and
hasfurnished thefirst evidence of CyA interfer-
ence with massive neutrophilic infiltration and
with hemopoietic signals. (Am J Pathol 1993,
142:1227-1237)
In recent years novel bis-benzimidazoles have been
recognized as effective anti-inflammatory agents.1-3
They were tested in the Lewis rat, which responds to
the systemic application of streptococcus group-A
cell wall-derived peptidoglycan polysaccharide (PG-
APS) with arthritis and with characteristic neutrophil-
assisted osteoclastic bone destruction and extensive
pyogranulomatous lesions in spleen and liver. Both of
the latter reactions were found to be uniquely sus-
ceptible to inhibition by trans-1,2-bis(5-amidino-2-
benzimidazolyl)ethene (BBE), one of many com-
pounds investigated.3 The drug appears to block
selectively the accumulation and activities of mac-
rophages, be it the modified macrophages of the os-
teoclast type or the cellular components of pa-
renchymal granulomata. In addition, it prevents the
association of neutrophils with the osteoclasts and the
influx of neutrophils into the granulomata. A further
distinguishing property of BBE is its ability to stimulate
splenic and hepatic macrophages to take up exces-
sive amounts of PG-APS and thus to become greatly
bloated.
To gain more information on its mode of action, BBE
has now been studied for its influence on the events
following the injection of PG-APS into a subcutaneous
air pouch in the Lewis rat. In these experiments the
streptococcal cell wall material is not disseminated
throughout the body as it is in the arthritis model.
Thus, any lesions encountered in sites other than the
pouch must be interpreted as secondary responses
to signals emanating from the pouch inflammatory
cells.
Reaching beyond BBE, two additional compounds
were included in the investigation. One was 1,2-bis-
(5-amidino-2-benzimidazolyl)ethane (BBE-d). It was
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added to evaluate the importance of the central dou-
ble bond for BBE activity. The other compound was
cyclosporine A (CyA), which is similar to BBE in its
antigranulomatous activity in the arthritis model4 and
for which interesting new properties were discovered.
Materials and Methods
Drug Sources
BBE and its single-bond derivative BBE-d were syn-
thesized according to previously established proce-
dures.5 Purity was assessed by nuclear magnetic
resonance spectroscopy, high-pressure liquid chro-
matography and elemental analysis (CHN). By
those criteria BBE was 100% pure and BBE-d was
95% pure. CyA was a product of Sandoz Pharma-
ceuticals Corporation (East Hanover, NJ). Cremo-
phor EL, the vehicle for CyA, was a gift from the
Sandoz Research Institute (East Hanover, NJ).
Streptococcal Cell Wall Fragments
PG-APS was used to stimulate inflammation in the
air pouches. The material was prepared from group
A, type 3, strain 58 streptococci by a previously de-
scribed method.6 The bacteria were broken up in a
Dyno Mill (Glenn Mills, Inc., Maywood, NY) at 40C.
Subsequently, glass beads and any remaining in-
tact cocci were removed by filtration and centrifuga-
tion. The cell fragments were collected by centrifu-
gation for 30 minutes at 30,000 x g. The material
was washed and extracted three times at 560C with
2% sodium dodecyl sulfate in phosphate-buffered
saline (pH 7.0). Following further washes, initially
with phosphate-buffered saline and then with dis-
tilled water, the cell wall fragments were lyophilized
and kept at 40C until use.
For application in the pouch experiments the cell
walls were suspended in saline and sonicated for
35 minutes at 40C. This was followed by 30 minutes
of centrifugation at 10,000 x g and passage of the
supernatant through a Millipore filter (0.45 pm) to
eliminate any clumped cell wall fragments. The
preparation was kept at 40C until injection into the
animals. Aseptic precautions were taken at all steps
in the procedure.
Animals
Pathogen-free female Lewis rats of an average
body weight of 200 g were obtained from Charles
River, Raleigh, NC. They were kept on an ad libitum
diet of Purina rat chow and water. An air pouch was
induced under light ether anesthesia by the injec-
tion of 10 ml of bacterium-free air under the subcu-
taneous striated muscle of the back. During the
course of a week the pouches were replenished
twice with a few milliliters of additional air. At the
end of the preparatory period the animals received
an injection into the pouch of either 4 ml saline or
saline containing 4.5 mg rhamnose equivalents of
PG-APS. Treatment with BBE, BBE-d, or CyA was
begun immediately afterward. BBE (10 mg/kg body
weight) and BBE-d (5 mg/kg body weight) were
given as single daily injections into the tail vein. The
compounds were dissolved in 0.4 ml of pyrogen-
free saline. Controls received saline only. CyA was
given into the muscle of the hind legs as a single
daily dose of 25 mg/kg body weight dissolved in 0.1
ml of Cremophor EL solution. The respective con-
trols received vehicle only. All injections were car-
ried out under light ether anesthesia, the last injec-
tions being given on the day before sacrifice. At
specified times the rats were killed by an overdose
of carbon dioxide. For a comparison of the effec-
tiveness of the three compounds one might note
that the daily doses of BBE, BBE-d, and CyA on a
molar basis had a ratio of 1:0.5:1.
Histological and Hematological Studies
At autopsy of the animals blood was withdrawn from
the heart, anticoagulated with potassium EDTA, and
then used in a model 150 Baker cell counter to de-
termine the white blood cell count, the red blood
cell count, and the hematocrit and hemoglobin val-
ues. Blood smears were prepared for differential
white blood cell counts.
The fluid contents of the air pouches were aspi-
rated. The volume was measured, and total and dif-
ferential white blood cell counts were performed.
Histologic examination was carried out on the air
pouches, spleens, livers, and knee joints, the latter
including part of the distal shaft of the femur and
the proximal shaft of the tibia. All specimens were
fixed in neutral formalin, and the bones were decal-
cified before embedding. The tissues were stained
routinely with hematoxylin and eosin and with the
periodic acid Schiff method (PAS) after diastase di-
gestion. Selected sections were also stained for iron
with Turnbull's Blue and for lipofuscin with a pro-
longed Ziehl-Neelsen procedure.
To determine the area of macrophages in pouch
tissue sections, the PAS-stained slides were placed
under the 40x objective on a Nikon Microphot-FXA
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microscope, and the resulting image was captured
by using an FG-100-AT image processor (Image
Technologies, Inc., Woburn, MA). The picture was
displayed on a Sony Trinitron Super Fine Pitch
color television monitor. By employing the Image
Measure/IP IM 2500 Morphometry System (Phoenix
Technology, Festival Way, WA) running under
Image-Pro 11 software (Media Cybernetics, Silver
Springs, MD) and using a mouse-type device con-
trolling a video cursor, morphometric measurements
of the cell areas were taken. The entire system was
run on an IBM AT computer.
Statistical Analyses
Student's t-test was used to determine the signifi-
cance of the difference between two means.
Results
The Pouch Reaction: Primary and
Secondary Events
The repeated injections of air into the dorsal subcu-
taneum of the Lewis rat led to the stereotyped pro-
duction of a pouch in the deep fascia. By the end of
1 week its wall consisted of 15 to 20 layers of fibro-
blasts peripheral to which there was a zone of vas-
cularization including capillaries, venules, and arte-
rioles. A few lymphocytes were scattered singly
throughout the tissue or grouped around small ves-
sels. Within a day after the introduction of PG-APS
into the pouch there was a significant acute inflam-
matory reaction characterized by an infiltration of
neutrophils and macrophages in the innermost lay-
ers of the wall. The majority of those neutrophils
were in transit and moved on into the pouch lumen.
The volume and white blood cell count of the puru-
lent exudate peaked by day 6 after PG-APS injec-
tion and then decreased rapidly over the following
three days (Figure 1). In contrast to the neutrophils,
the macrophages remained in the pouch wall in
much greater numbers. They acquired increasing
amounts of PG-APS and could be easily identified
histologically because of the PAS staining of the in-
gested material. The percentage of macrophages in
the pouch exudate did not exceed 10% of the total
white cell count. It should be noted that the neutro-
phils also took up PG-APS, albeit in small amounts.
The inflammatory process led to further thickening
of the pouch wall by stimulating capillary and fibro-
blastic proliferation, which reached its height on day


















DAYS AFTER PG-APS INJECTION INTO AIR POUCH
Figure 1. Total number of neutrophils removed from the pouch lu-
mina at various times after PG-APS injection. There was no drug
treatment. Each point represents mean ± SEM of 4 animals.
the experiments lymphocytes remained scarce in
the pouch tissue. A few small groups of perivascu-
lar plasma cells were observed 9 days into the
pouch inflammation.
At the time that the inflammation ran its course in
the air pouch, striking changes also took place in
the spleen. In the red pulp there developed exten-
sive hemopoiesis, including proliferation of myeloid,
megakaryocytic, and erythroid elements. From the
graphs in Figure 2 it can be seen that the mega-
karyocyte counts on transverse sections of the
spleens closely paralleled the degree of involve-
ment of the red pulp, and the counts can therefore
serve as general measure of the hemopoietic activ-
ity. Stimulation was noticeable as early as 1 day af-






















2 DAYS AFTER PG-APS INJECTION INTO AIR POUCH
Figure 2. Splenic megakaryocyte counts and extent of hemopoietic
replacement of the red pulp at various times after PG-APS injection
into the pouch. There was no drug treatment. The groups were made
up of 4 animals. Megakaryocytes were counted on two sections of
each spleen. Values are means ± SEM.
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rapid increase occurred on days 4 to 6, while be-
yond day 6 the values began to decline and had re-
turned to the baseline by day 17. As could be ex-
pected, hemopoiesis was temporarily enhanced
also in the bone marrow, causing a complementary
reduction in adipose tissue. It should be noted that
in rats with PG-APS-injected pouches none of the
material was carried away beyond the confines of
the pouch wall. This differed from the experience
with the intraperitoneal route of administration, in
which case PG-APS was removed by macrophages
from the abdominal cavity and transported to liver
as well as to spleen.
Effect of BBE, BBE-d, and CyA on the
Pouch Lesions
As detailed in Materials and Methods, drug treat-
ment began immediately after the application of
PG-APS into the air pouch and consisted of single
daily doses of the compounds, the last one being
given on the day before sacrifice. Testing of each
drug involved four groups of animals. Two groups
received PG-APS and either drug or vehicle. Two
more groups received saline and either drug or ve-
hicle. In the following, use of the unspecified term
"controls" refers to animals that had received PG-
APS but no drug. Already early in the experiments it
was obvious that CyA and BBE had a beneficial ef-
fect on the pouch reaction, and this became more
pronounced as the disease advanced. Under the
influence of those two drugs the pouches remained
flaccid and collapsed, while in the controls they
progressively enlarged and felt very tense. At the
height of the pouch response, 6 days after PG-APS
injection, about 2 to 4 ml of pus could be aspirated
in the controls. No fluid could be removed from the
CyA animals, and only a trace could be obtained
from the BBE group. With BBE-d, on the other hand,
the amount of exudate virtually matched the con-
trols. Table 1 allows a comparison of the results in
terms of numbers of white blood cells present in the
pouches. For all controls and for the BBE-d group
the percentage of neutrophils in the exudate was
about 90%, macrophages accounting for the rest.
In the BBE group macrophages made up about
50% of the very low total white blood cell count.
Histological examination of the pouches in the CyA
and BBE animals showed only rare small collections
of neutrophils in the inner pouch wall and in the
pouch lumen, markedly less than were seen in the
controls and in the BBE-d group (Figure 3).
Table 1. Number of Neutrophils in Air Pouch Lumina
ofDrug-Treated Rats and of 7Teir Respective
Vehicle-Treated Controls
No. of neutrophils
per pouch (x 10-6)t
Treatment* Controls Drug-treated
BBE 541 ± 508 1.3 ± 3.3t
BBE-d 361 ± 232 356 ± 121
CyA 369 ± 282 0
The rats were killed 6 days after PG-APS injection into the
pouch. n = 5 or 6.
t Values are means ± SD.
t P< 0.05.
While with the neutrophils their total number in
the pouch was of chief interest, with the abundantly
present macrophages in the wall it was their varia-
tion in size that drew the most attention. As early as
3 days after PG-APS injection it was histologically
evident that the cut surface areas of the macro-
phages were larger in the BBE and BBE-d groups
than in their respective controls or in the CyA group.
By day 9 the values had become stabilized, and the
difference had become easily discernible on micro-
scopic examination (Figure 4). Morphometric mea-
surements at that time revealed that in the BBE and
BBE-d groups the macrophages had about twice
the area size as in the controls (Figure 5). Taking
into consideration the constant size of the macro-
phage nuclei, one could calculate that the cytoplas-
mic volumes of the cells had about tripled. The in-
crease in volume was due to a marked increase in
ingested PG-APS. Analysis of the morphometric
data of the CyA-treated animals also revealed a sta-
tistically significant increase in cell size. However,
the compound was distinctly less active than either
BBE or BBE-d, whether doses were compared on a
weight or molar basis.
Effect of Drug Treatment on Splenic
Hemopoietic Hyperplasia
The influence of the drugs on PG-APS-induced,
pouch-dependent hemopoietic hyperplasia in the
spleen was judged by the megakaryocyte count,
the overall degree of occupancy of the red pulp by
the proliferating cells and by evaluation of the prev-
alence of the three cell lines. The megakaryocyte
counts were obtained generally on day 6 and day 9
after PG-APS injection where high values could be
expected. For BBE the two groups of PG-APS-free
controls for the 6-day time point were not available
and were replaced by the 7-day values. This did not
interfere with the interpretation of the data. As can
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Figure 3. Wall ofairpoucb 6 days after injection ofPG-APS. A, heavy neutrophilic infiltrate in saline-treated control. B, no inflammation in an-





im - --.' # .
Figure 4. PG-APS-laden pouch macrophages 9 days after PG-APS injection. A, small macrophages in saline control rat. B, enlarged macrophages
in BBE-treated animal. PAS digest, x 162.
be seen in Figures 6A and 6B, neither BBE nor
BBE-d had any significant effect on the megakaryo-
cyte count. There was no reduction in PG-APS-
elicited megakaryocytic hyperplasia, and there was
also no decrease in the baseline count in animals
that had not received PG-APS. For CyA there was
quite a different response. The megakaryocytic hy-
perplasia was completely eliminated, and even the
baseline values fell significantly further (Figure 6C).
In agreement with the megakaryocyte data there
was complete absence in the spleen of myeloid and
erythroid precursors in the CyA-treated animals
(Figure 7). In the BBE-d series there was suppres-
sion of the two cell lines on day 6, the red pulp oc-
cupancy rate being down to 5% from the controls'
60%. However, on day 9 there was no longer any
discernible difference between the BBE-d-treated
group and the control group. For the BBE group it
was of interest that myeloid precursors were plenti-
ful in the red pulp, while no erythroid elements were
encountered (Figure 8).
Drug-Induced Stimulation of Splenic
Macrophages
The spleens of all rats used in these experiments
had easily identifiable yellow pigment deposits
within groups of macrophages in the red pulp. The
pigment was in the shape of granules or small
blocks which assumed an orange color with the
PAS digest procedure. It also was acid-fast and
stained heavily with the iron stain. This combination
of reactions sets it apart from PG-APS and identifies
it as wear-and-tear pigment. The material became
of interest when it was noted to be redistributed in
animals that had received BBE or BBE-d, but not in
those that had received CyA. Instead of being
present as small collections in the cytoplasm of
many macrophages, it was now concentrated as
large deposits in only a few macrophages (Figure
9). It should be noted that the reaction occurred
whether the animals had also been given PG-APS
or not. No changes took place in the Kupffer cells
1232 Geratz et al




Figure 5. Increased cut surface area ofpouch macrophages in rats
treated with BBE, BBE-d, or CyA. The experimental groups comprised
S or 6 animals which uere killed 9 days after injection of PG-APS
into the pouch. In each animal 100 or 200 cells were measured. Val-
ues are means ± SEM. P < 0.001 for each of the three sets.
because they were free of any stored material that
could have been rearranged.
Effect of Drug Treatment on Hemopoiesis
in the Bone Marrow and on Circulating
White Blood Cell and Hemoglobin Values
The degree of hemopoiesis in the bone marrow was
evaluated by inspection of the distal femoral and
proximal tibial epiphyses. In animals unchallenged
by either PG-APS or drugs about 60% of the mar-
row spaces were occupied by myeloid, erythroid,
and megakaryocytic cells, while the remaining 40%
were filled with adipose tissue. Three days after the
injection of PG-APS into the pouches the fat was re-
duced to 15%, and on days 6 and 9 it was down to
5 to 10%. Most of the decrease could be attributed
to expansion of the number of maturing myeloid
cells. CyA completely blocked this hyperplasia and
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DAYS AFTER 6 6 6 6
POUCH INJECTION
PG-APS IN POUCH - - + +
BBE-d - + - +
9 9 9 9
Figure 6. Splenic megakaryocyte counts in rats that had or had not received an
injection ofPG-APS into the pouch and that also had or had not received daily
drug treatment. The individual groups were made up of 4 to 6 animals, and two
sections of each spleen were counted. Values are means ± SEM. A, B, animals
that had received PG-APS show the expected rise in megakaryocyte counts, but
neither BBE nor BBE-d displays any suppressive effect. C, inhibitory effect ofCyA
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Figure 7. Splenic redpulp in rats 6 days after injection ofPG-APS into the pouch. A, trilineage hemopoiesis in saline-treated control. B, absence of
megakaryocytic, mveloid and erythroid elements in animal treated uwith CyA. H&E, X323.
Figure 8. Splenic hemopoiesis in rats 6 days after injection ofPG-APS into the pouch. A, presence of all three cell lines in saline-treated control. B,





Figure 9. Iron pigment-containing splenic macrophages in rats that had been given saline, but not PG-APS, into thepouch on day 0 and that had
received 9 daily i.v. injections of either saline or BBE. A, small macrophages in saline control. B, enlarged macrophages in BBE-treated animal.
Turnbull's blue, X 485.
on the other hand, showed no such beneficial activ-
ity, and BBE, as it did in the spleen, greatly de-
creased the number of red cell precursors. This re-
duction occurred even if the animals had received
the drug only and no PG-APS (Figure 11). Myeloid
elements partially filled in for the erythroid compo-
nents.
To complement the findings in the bone marrow,
the impact of the drugs on the circulating white
blood cells and on hemoglobin levels was also
studied. Data were collected for days 6 and 9 after
PG-APS injection. Because of the similarity of the
findings at the two time points, however, only the
day 9 results are presented (Table 2). For each of
1234 Geratz et al





Figure 10. Bonie marrou ini distalfemoral epiphysis in rats 6 days after inijectioni ofPG-APS into poich. A, mtarked hemopoietic hiperplasia uwith
replacemenit of allfat cells in,salinie-treated conitrol. B, niormal ratio between hemopoietic elements anzdfat cells in anlimal treated with daily i.m.
injectionis of CyA. H&E, X 323.
Figure 11. Distal femoral epiphvsis in rats uwich had ani established air poutchb buit uhich had not receiived PG-APS. A, niormal trilinzeage he-
miopoiesis in rat which was giiven 7 daib' in/ectionis of ivehicle inito the poioch. B, selectiive absence ofJ -ed cell precuirswor in rat wihich hacd receitved 7
claily, in/ection.s of BBE. HE. X 323.
the three compounds there is one group of animals
which received PG-APS only and a second group
which received PG-APS and the respective drug.
As BBE alone had an effect on the values, an addi-
tional pair of controls was included with this com-
pound, ie, one group that had received the drug
and no PG-APS and another one that had received
neither PG-APS nor drug. The latter group can also
serve as baseline control for BBE-d and CyA. Two
observations can be made on the white blood cell
data. First, for all three groups that had been given
the drugs the monocyte and lymphocyte counts
were higher than in the controls. Second, BBE-d
and CyA did not affect the neutrophil number in the
circulation, while BBE, with or without PG-APS ad-
ministration, produced significant neutrophilia.
There was no deleterious effect of BBE-d or CyA
on the blood hemoglobin levels. With BBE, however,
the suppressive activity on erythropoiesis found its
expression in a normocytic anemia with a fall in
blood hemoglobin values over the 9-day period
from 15.1 to 11.6 g/100 ml.
Discussion
These studies of PG-APS-induced inflammation
have expanded our knowledge of the primary
events in the air pouch and of the secondary
changes in spleen, bone marrow, and circulating
blood. As summarized in Table 3 they have also re-
vealed distinctive differences between the modulat-
ing effects of CyA, BBE, and BBE-d, and these re-
sults make it possible to speculate on possible
pathogenetic mechanisms. At the very beginning of
the pouch reaction, macrophages and neutrophils
are thought to be directed toward PG-APS by
chemotaxis. With increasing activation of macro-
phages, however, secreted interleukin-1 (IL-1) prob-
r
}
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Table 2. Influence ofBBE, BBE-d, and CyA on the Number of Circulating White Blood Cells
Injections White blood cells (no. per mm3 x 10-3)*
Drug Pouch i.v. or i.m. Lymphocytes Monocytes Neutrophils
BBE PG-APS BBE 11.8 ± 3.3 1.3 ± 0.6 4.3 ± 1.9
PG-APS Saline 6.7 ± 0.7 0.2 ± 0.1 0.7 ± 0.2
Saline BBE 10.9 ± 0.7 1.7 ± 0.6 3.5 ± 1.5
Saline Saline 6.0 ± 1.5 0.3 ± 0.1 0.7 ± 0.2
BBE-d PG-APS BBE-d 18.5 ± 2.7 3.2 ± 0.5 2.7 ± 0.6
PG-APS Saline 8.8 ± 1.4 0.4 ± 0.1 1.6 ± 0.2
CyA PG-APS CyA 10.4 ± 1.7 1.2 ± 0.7 1.6 ± 0.4
PG-APS Vehicle 6.8 ± 1.7 0.5 ± 0.2 1.9 ± 0.4
Blood was collected at the time of sacrifice, 9 days after PG-APS injection.
Injections of BBE and BBE-d were i.v., those of CyA were i.m. n = 5 or 6. Values are means ± SD. i.v., intravenous; i.m., intramuscular.
Table 3. Modulation ofEvents in Pouch Model by BBE,
BBE-d, and CYA
Event BBE BBE-d CyA
Inhibition of pouch Yes No Yes
neutrophilic infiltration
Enlargement of Yes Yes Slight
PG-APS-laden pouch
macrophages
Increased size of splenic Yes Yes No
storage macrophages
Inhibition of trilineage Erythropoiesis Partial Yes
hemopoietic hyperplasia only
in spleen
Inhibition of trilineage Erythropoiesis No Yes
hemopoietic hyperplasia only
in bone marrow
Anemia Yes No No
Blood neutrophilia Yes No No
independent of PG-APS
administration
Lymphocytosis and Yes Yes Yes
monocytosis in PG-APS
recipients
ably becomes the driving factor, causing neutrophil
extravasation by promoting adhesion to the endo-
thelium and facilitating emigration.7 8 CyA, on the
other hand, can down-regulate IL-1 production, and
this would explain its ability to block the influx of
neutrophils into the pouch.9 Chemotaxis itself, at
least under in vitro conditions, is not susceptible to
inhibition by CyA.10-12 In addition to the current
study, in vivo suppression of neutrophil tissue infil-
tration by CyA has been described in only two situ-
ations. In one, the drug reduced the severity of the
acute inflammatory cell accumulation that develops
during reperfusion of temporarily ischemic intes-
tine.13 In the other, a beneficial effect of CyA was
found in pyoderma gangrenosum, where it pro-
moted the clearing of the mixed acute and chronic
inflammatory infiltrate in the skin.14
In the PG-APS-dependent arthritis model, BBE
treatment prevented the appearance of neutrophils
in the bone marrow of the distal tibia, where they
would otherwise have been important participants
in the osteodestructive process.3 Furthermore, BBE
blocked the characteristic immigration of neutro-
phils into splenic and hepatic granulomata. Those
observations together with the current experience
with the air pouch suggest that the antiinflam-
matory activity of BBE is a more general phenome-
non than initially assumed. As with CyA, macro-
phages probably represent the target of the antiphl-
ogistic effect of BBE, although the actual mecha-
nism of interference is still uncertain. Nevertheless,
the interaction of BBE with its binding site must be
of high specificity. This is evident from the fact that
the overall rather minor change of saturating the
central double bond of BBE, and thus turning it into
BBE-d, eliminated all antineutrophil activity.
One of the surprising findings in the arthritis stud-
ies had been the striking BBE-induced enlargement
of PG-APS-laden macrophages in spleen and liver.3
Now it has become evident that oversized mac-
rophages can occur in tissues other than those two
organs and that BBE-d and, to a lesser degree,
CyA can also promote the uptake of streptococcal
cell wall. Moreover, histological examination of the
spleen has shown that excessive storage of mate-
rial in macrophages is not restricted to PG-APS de-
posits. Under the influence of BBE and of BBE-d
there occurred a redistribution of lipofuscin and
iron-containing pigment, some macrophages gain-
ing a large amount and others losing most of their
contents. These observations dispel the notion that
such stored materials are permanently locked away
and would not be subject to further handling. As the
drugs obviously alter lysosomal function, it would
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be of great interest to know how they would influ-
ence reticuloendothelial and parenchymal cells in
lysosomal storage diseases, such as sphingolipi-
doses and mucopolysaccharidoses.
In the pouch model as well as in the arthritis
model hemopoietic hyperplasia in the long bones
and in the spleen are characteristic features of the
disease process. However, there exists a disparity
between the two experimental designs in the timing
of the histological changes. In the pouch animals
proliferation in the two locations developed concur-
rently, peaked between days 6 and 9, and had sub-
sided by day 17. In the arthritis model, on the other
hand, bone marrow hyperplasia was first noted by
day 3, while splenic hemopoiesis became obvious
3 days later, by day 6.2 The involvement of the long
bones reached a prolonged high plateau by day 6,
and the splenic changes again lagged 3 days be-
hind, achieving a high plateau by day 9. The se-
quence of events in the two experimental systems
was probably a reflection of the pattern of release of
stimulating mediators. In the pouch model there
most likely was a single pulselike discharge of the
agents responsible. In the arthritis model it appears
that the initial stimulus might have originated in the
bone marrow macrophages, which are known to ac-
quire PG-APS.15 The splenic hemopoiesis, however,
and possibly also the persistent hyperplasia in the
bone marrow, are best attributed to the release of
cytokines from the increasingly more massive
splenic and hepatic granulomata. Those granulo-
mata are already known to be involved in the syn-
thesis and secretion of IL-1, IL-2, and IL-3.16 Partic-
ipation of cytokines is supported by the experience
of other investigators who have shown that
interleukins-1, -2, -3, and -6 are elevated in the hy-
perplastic bone marrow of rats with collagen-
induced arthritis17 18 and that interleukins-1 and -6
are increased in the marrow of animals with yet an-
other type of arthritis, ie, adjuvant-induced arthri-
tis.18 From these data it is probably safe to con-
clude that the antihemopoietic properties of CyA
are based on the reduction of cytokine activity. Al-
though this interference is beneficial to the animals
in the PG-APS-induced disease model, one won-
ders what role cytokines might play in the regulation
of normal hemopoiesis and if treatment with CyA
might cause or intensify anemia in humans.
At this point there is no satisfactory explanation
for the selective inhibition of erythropoiesis by BBE.
Conceivably, it could be a toxic effect, it could result
from competition for growth factor receptors, or
it could be due to inhibition of the function of the
nurturing macrophages of the erythroblastic is-
lands.19-22 It is also uncertain at this point if the
neutrophilia caused by BBE is connected to the
anti-erythroid activity.
Additional studies will be necessary to determine
if the lymphocytosis and monocytosis associated
with all three drugs are due to increased cell mobi-
lization or to prolonged intravascular retention of the
cells.
In summary, streptococcal cell wall-induced in-
flammation in the rat air pouch has proved a valu-
able system for the testing of the antiphlogistic
effects of macrophage-directed compounds. As
demonstrated above, size of the macrophages,
number of infiltrating neutrophils, and degree of he-
mopoietic stimulation in spleen and bone marrow
are some of the parameters that can be explored.
The model has revealed new interventional proper-
ties of CyA, and its use is recommended in future
evaluation of CyA-like agents.
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